Jeuveau/Nabota 100 IU (Korean Packaging) 1 vial

This treatment is strictly contraindicated. No clinical safety data exists for botulinum toxin use during pregnancy. We prioritize safety and defer all elective neurotoxin treatments until after the breastfeeding period has completely concluded.

The formulation contains 100 International Units of sterile Clostridium Botulinum Toxin Type A (PrabotulinumtoxinA-xvfs), with Human Serum Albumin (0.5 mg) and Sodium Chloride (0.9 mg) as stabilizers.

Not advised while breastfeeding due to insufficient data on toxin/metabolite transfer into breast milk and potential infant risk. Defer treatment until breastfeeding has concluded.

Common reactions include headache, temporary injection site pain, and localized swelling. There is also a potential for purple bruising at the entry points. To ensure a quick recovery, patients should follow our expert aftercare guide (adapted for toxins). Any drooping of the eyelid (ptosis) is a known but rare side effect that usually resolves within a few weeks.

The active substance, PrabotulinumtoxinA, acts as a neuromuscular blocking agent by inhibiting the release of acetylcholine. This prevents muscle contraction in the treated area, allowing the overlying skin to smooth out. Unlike superficial skin boosters that focus on dermal hydration, Nabota targets the muscular cause of dynamic wrinkles. This relaxation is often a key component of the Russian lips filler technique to reduce perioral tension.

Dosage is individualized based on the muscle strength and the target area. For glabellar lines, the standard protocol is 20 units divided into five injection sites (4 units per point). Practitioners should evaluate if subtle micro-dosing is sufficient for early-stage wrinkles. Reconstitution typically involves adding 2.5 ml of saline to the 100U vial to yield a concentration of 4 units per 0.1 ml.

Avoid alcohol for 24h before and after the procedure. Alcohol is a vasodilator that can increase blood flow, potentially worsening post-injection swelling and increasing the risk of visible bruising at the needle entry points.